Stockreport

Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis

Cogent Biosciences, Inc.  (COGT) 
Last cogent biosciences, inc. earnings: 11/8 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.cogint.com/investor-relations
PDF 413 patients enrolled in PEAK Phase 3 GIST trial, exceeding enrollment target; top-line results expected by end of 2025 PEAK interim futility analysis completed with no [Read more]